37results about How to "Reduce TG content" patented technology

The invention relates to a liver-protecting and antialcoholismic oral liquid and a preparation process thereof, belonging to the technical field of health care products. The liver-protecting and antialcoholismic oral liquid comprises the following components in parts by weight: 50-200 parts of lucid ganoderma, 20-250 parts of radix puerariae, 20-100 parts of semen hoveniae, 20-50 parts of shizandra berry and 10-50 parts of liquorice. The liver-protecting and antialcoholismic oral liquid not only has the function of nourishing and protecting the liver, but also has the efficacy of disintoxication.

The invention provides application of geniposide in preparation of a medicine for treating fatty liver disease, and relates to novel application of the geniposide. The geniposide can be used for preparing the medicine for treating fatty liver disease. The medicine can be prepared into commonly used clinical preparation according to conventional method, and the oral solid preparation is better, such as granule, tablet and capsule. The medicine contains 50 to 100mg / kg of geniposide by weight. The medicine is subjected to the test on high fat diet-induced golden hamster with fatty liver disease; and as the test shown, the medicine can obviously reduce the contents of serum TG (Triacylglycerol) and the content of liver tissue TG, and inhibit the raise of the activity of serum ALT (Glutamic-Pyruvic Transaminase) and AST (Glutamic Oxalacetic Transaminase), and has the effect of treating the fatty liver disease, so that the geniposide can be used for preparing the medicine for treating the fatty liver disease.

The invention provides an application of lactobacillus plantarum powder in regulating fat metabolism and intestinal flora of fat rats. The lactobacillus plantarum powder can reduce the in-vivo fat content, increased under induction of high-fat diet, of rats and reduce the body fat rate; the FFA content, increased under induction of high-fat diet, in serum of rats can be remarkably reduced; meanwhile, the TG content in the serum of obese rats can be reduced, and the HDL-C content is increased; the lipid metabolism function of the livers of the obese rats can be improved, and activation of a fatty acid synthesis pathway of the obese rats is inhibited; the condition of intestinal flora disorder of the obese rats can be improved, and the flora richness, flora diversity, flora structure and composition of the obese rats can be maintained; increase of relative abundance of firmicutes is inhibited; the relative abundance of bacteroides is improved; the relative abundance ratio of the firmicutes to the bacteroides in intestinal tracts of rats under the condition of high fat diet is reduced; and the similarity of intestinal flora of the obese rats and healthy rats is increased.

The invention discloses a preparation method of mollugin. The preparation method includes: taking India madder root, and using 5-15 times of petroleum ether to perform heating reflux extraction for 20-40min; recycling petroleum ether, and vacuum drying to remove petroleum ether so as to obtain extract; and subjecting the extract to 200-300-mesh silica gel column chromatography, eluting with petroleum ether, performing TLC (thin layer chromatography) detection, combining components rich in mollugin, subjecting to Sephadex LH-20 gel column chromatography, eluting with mixture of chloroform, petroleum ether, and methanol in mass ratio of 5:5:1, subjecting to silica gel H-column decompression column chromatography, eluting with petroleum ether, and recrystalizing with hot ethanol to obtain the mollugin. The invention further discloses application of the mollugin in preparation of hypoglycemic drugs and preparation of drugs for treating diabetes. Experiments show that the mollugin can effectively reduce blood sugar, TC (total cholesterol), TG (total glycerin) and MDA (methylene dioxyamphetamine) content of mice with high blood sugar caused by alloxan, and can evidently increase SOD (superoxide dismutase) activity and hepatic glycogen content of the mice.

The invention discloses a medicinal composition for preventing or treating nonalcoholic steatohepatitis. The composition consists of gynostemma pentaphylla, radix curcumae, rhizoma atractylodis macrocephalae, silybum marianum, rhizoma alismatis, poria cocos, semen cassiae, salvia miltiorrhiza, seman sinapis albae and hawthorn. The medicinal composition disclosed by the invention has the functions of invigorating the spleen, soothing the liver, activating blood and eliminating turbid, and has an obvious effect on preventing or treating nonalcoholic steatohepatitis.

The invention relates to an aminomethyl substituted silybin derivative as shown in formula (I) and pharmaceutical salt or solvate thereof. The invention further relates to a preparation method and medical application of the compound as shown in formula (I) and a pharmaceutical composition of the compound. The compound has effects of treating liver injury, resisting oxidation and regulating dyslipidemia and can be used as medicine for treating diseases such as liver injury, non-alcoholic fatty liver disease, hepatitis B, hepatitis C, hepatic fibrosis and liver cancer.

The invention belongs to the technical field of biological pharmacy, and discloses application of Piceatannol 3'-O-glucoside in preparation of a product for treating and / or preventing non-alcoholic fatty liver disease. Researches show that after the Piceatannol 3'-O-glucoside is continuously administrated to a non-alcoholic fatty liver disease (NAFLD) model mouse for four weeks, the contents of TC, TG and LDL in serum are remarkably reduced and the content of HDL is remarkably increased, which shows that the medicine has a lipid regulating effect; activity of AST and ALT in serum is remarkablyweakened and infiltration of inflammatory factors in liver tissue is relieved, which shows that the medicine has a liver protection effect; the fat content of the liver can be reduced and the pathological form of the fatty liver can be improved, which indicates that the medicine has an antagonistic effect on NASH. The test result shows that the Piceatannol 3'-O-glucoside has good development andapplication value in the aspect of preventing and treating the non-alcoholic fatty liver disease.

The invention provides a compound liver-protecting traditional Chinese medicine for treating non-alcoholic fatty liver disease (NAFLD), which comprises the following components in parts by weight: 2-10 parts of chitosan oligosaccharide, 3-20 parts of salidroside, 5-10 parts of resveratrol, 10-20 parts of astaxanthin and 5-15 parts of stichopus japomicus slelenka glycosaminoglycans. According to the invention, through NAFLD mouse model experiments in vivo and vitro, five bioactive ingredients of the salidroside, chitosan oligosaccharide, resveratrol, astaxanthin and stichopus japomicus slelenka glycosaminoglycans are determined by a cell and molecular biology method, and after the bioactive ingredients are scientifically proportioned, lipid metabolism related genes can be adjusted, the effect of reducing the content of triglyceride in NAFLD liver cells is obvious, cell apoptosis induced by fatty acid can be relieved, hepatic steatosis of high-fat diet mice can be relieved, the TG content in the liver can be reduced, the medicine does not have obvious side effects and has no cytotoxicity, and the immune balance of the organism can not be damaged.

The invention provides application of oligomeric stilbene compounds in preparing medicine for preventing and / or treating glucose and lipid metabolism disorder. By extracting the nine oligomeric stilbene compounds from iris lacteal seeds for activity research, it is proved that the compounds can inhibit adipocyte differentiation, improve the insulin resistance and improve the sensitivity of adipocyte to insulin, so that the compounds are used for preparing the medicine for preventing or treating obesity, type II diabetes and other metabolic disorders.

The invention provides a lophatherum gracile composition with a body-weight reducing effect and a preparation method thereof. The composition is prepared from lophatherum gracile extract, dandelion extract, flos sophorae extract, bitter apricot kernel extract, momordica grosvenori extract, poria cocos extract, coix seed extract, pericarpium citri reticulatae extract, haw extract, semen raphani extract and lotus leaf extract serving as effective ingredients and auxiliaries which are permitted to use in medicines and foods. Animal experiments indicate that the lophatherum gracile composition can be used for remarkably reducing the content of CHO, LDL and TG in serum, and reducing a certain content of fat in the body, and indicates that the composition has a body-weight reducing effect.

The invention discloses a medicine for treating rheumatoid arthritis and a preparation method thereof. The medicine comprises the ingredients of Chinese parsnip root, glabrous sarcandra herb, berba aristolochiae mollissimae, erycibe obtusifolia benth, Chinese Starjasmine Stem, tuber fleeceflower stem, Chinese Ivy Stem and the like which are called 'Three-Feng Four-Teng Soup'. The preparation method comprises the steps of cleaning, soaking, decocting and the like, all the raw materials are used in combination, and all the medicines cooperate in effects to effectively treat rheumatoid arthritis and effectively control the relapse of rheumatoid arthritis. The medicine for treating rheumatoid arthritis has the functions of suppressing fungi, dispelling wind to eliminate dampness, activating blood circulation to dissipate stasis, eliminating stagnation to stop pain, and clearing and activating the channels and collaterals, is high in efficiency and cure rate when used for treating rheumatoid arthritis, has no toxic and adverse effects and good safety, and is easy to prepare, low in cost and price and suitable for patients.

The invention discloses an application of a rosa roxburghii triterpenoid extract in preparation of drugs, health-care products and health-care food for preventing and treating alcoholic liver disease.Provided are the drugs and health-care products for preventing and treating alcoholic liver disease, wherein the drugs and health-care products comprise 2-99% of the rosa roxburghii triterpenoid extract, and the rosa roxburghii triterpenoid extract is used as an active ingredient. The invention also provides health-care drinks suitable for patients with alcoholic liver disease, wherein the health-care drinks comprise 0.05-0.7% of the rosa roxburghii triterpenoid extract. The health-care drinks comprise alcoholic drinks, fruit-flavored beer drinks, grape wine drinks and the like. Through implementation of a most recognized model of alcoholic liver disease in mice, the rosa roxburghii triterpenoid extract is found out to alleviate the liver pathological changes induced by alcohol in different extents; liver enlargement, weight gain and fat accumulation degree are significantly improved; biochemical and pathological indicators are decreased; the level of triglycerides in liver is significantly reduced. Therefore, the rosa roxburghii triterpenoid extract can prevent and treat alcoholic liver disease, can be used as drugs separately or in combination, and is used for developing corresponding drugs, health-care products or health-care food.

The invention relates to a preparing method of lecithin of tuna roes. The method comprises the steps of 1) enzymolysis,wherein distilled water and trypsin are added into tuna roe homogenate for enzymolysis, and centrifugation is conducted after inactivation to remove supernatant; 2) digestion, wherein acetone is added into a filter cake after enzymolysis, stirring and suction filtration are conducted, and then acetone is utilized for digestion until the color of the acetone does not change; 3) secondary digestion, wherein absolute ethyl alcohol is added into the filter cake after digestion, and microwave digestion is conducted intermittently; 4) purification, a CHCl3-CH3OH(2:1) mixed solution is taken as an eluent to conduct silica gel chromatography column purification on a crude lecithinproduct, and the eluent is collected and dried to obtain the pure lecithin product. By means of the method, the extraction speed of free phospholipid can be increased, the extraction rate is increased, and then the finished product lecithin can be obtained through silica gel chromatography column purification; the purity is improved on the basis of significantly increasing the extraction rate ofthe lecithin, further direct application of the lecithin is facilitated, and the lecithin of the tuna roes can be applied to inhibition of human liver cancer HepG2 cells and lipid decreasing of Changliver cells.

The invention discloses a new flavonoid Hip A and application thereof. The new flavonoid Hip A is prepared by the following steps: eluting a sea buckthorn seed meal extract by an MCI gel column, and then performing semi-preparative separation by a C18 chromatographic column, a diol chromatographic column and a C18 chromatographic column in sequence to obtain the new flavonoid Hip A. The inventionalso provides an application of the new compound Hip A in preparation of a drug for preventing and / or treating lipid metabolism disorder. Through activity research on the compound Hip A, it is verified that the compound Hip A can inhibit cell lipid generation and can be used for preparing drugs for preventing or treating obesity, hyperlipidemia and other lipid metabolism disorder diseases.

The invention relates to a traditional Chinese medicine composition for resisting eimeria tenella, which comprises the following raw medicines: kuh-seng, dichroa root, polygonum aviculare, chinaberry bark, pulsatilla chinensis, sealwort and white peony root. According to the Chinese veterinary medicine theory, the clinical characters of coccidiosis and the characteristics of chicken diseases, the invention develops a traditional Chinese medicine composition for resisting eimeria tenella. The traditional Chinese medicine composition has the prescription principles of mainly clearing away heat and drying dampness as well as cooling the blood to stop bleeding and reinforcing deficiency in an auxiliary way, is prepared by screening, and has an obvious curative effect on chicken coccidiosis through actual use.

The invention discloses an application of total flavonoids of rosa roxburghii in preparation of drugs, health-care products and health-care food for preventing and treating alcoholic liver disease. Provided are drugs and health-care products for preventing and treating alcoholic liver disease, wherein the drugs and health-care products comprise 3-99% of the total flavonoids extract of rosa roxburghii, and the total flavonoids extract of rosa roxburghii are used as an active ingredient. The invention also provides health-care drinks suitable for patients with alcoholic liver disease, wherein the health-care drinks comprise 0.08-1% of the total flavonoids of rosa roxburghii. Through implementation of a most recognized model of alcoholic liver disease in mice, the total flavonoids of rosa roxburghii are found out to obviously alleviate the liver pathological changes induced by alcohol; liver enlargement, weight gain, fat accumulation and inflammatory infiltration degree are significantlyimproved; biochemical and pathological indicators are decreased greatly. Therefore, the total flavonoids of rosa roxburghii can prevent and treat alcoholic liver disease, can be used as drugs separately or in combination and are used for developing corresponding drugs, health-care products or health-care food.

The invention discloses application of blended edible oil compounded of sunflower seed oil and lard in the aspect of obesity resistance. The blended edible oil is prepared by compounding sunflower seed oil and lard, as well as adding 1wt% of caprin; and the prepared blended edible oil compounded of the sunflower seed oil and the lard is for daily consumption use. The blended edible oil compoundedof the sunflower seed oil and the lard disclosed by the invention is simple in proportion, low in cost and good in compatibility; being taken at an intake amount of 25-50 grams per person per day, theblended edible oil is capable of preventing hepatic adipose infiltration and improving lipid metabolism after long-term consumption, thereby achieving the functions of effectively reducing body weight, body fat ratio, fat cell volume, hepatic TG deposition and the like.

The invention belongs to the field of health-care products and particularly relates to a dual-purpose medical and edible composition with a blood fat reducing function and a preparing method of the dual-purpose medical and edible composition. The dual-purpose medical and edible composition with the blood fat reducing function is mainly prepared from natto extract, earthworm extract, bamboo leaf flavonoid, hawthorn extract, pueraria extract, ginseng extract, green tea extract, chitosan oligosaccharide and a sweetening agent. The dual-purpose medical and edible composition with the blood fat reducing function can obviously reduce the TC and TG content of serum of hyperlipidemia rats, and can also obviously reduce the high shearing viscosity, medium shearing viscosity and low shearing viscosity of the blood of the hyperlipidemia rats, and thus it is indicated that the dual-purpose medical and edible composition with the blood fat reducing function has the obvious blood fat reducing effect. In addition, the composition is definite in effective ingredient, controllable in quality, low in toxic and side effect, high in safety and suitable for being taken in a long term and is ideal blood fat reducing health-care food.

The invention belongs to the field of medicine. The invention relates to a hawthorn flavone-total tanshinone composition and an application thereof in preparation of drugs and / or health care productsfor preventing and / or treating non-alcoholic fatty liver. The invention also provides an application of the hawthorn flavone-total tanshinone composition in health care products, and drinks prepared by taking the hawthorn flavone-total tanshinone composition as an active ingredient and mixing with food acceptable additives; the invention provides but is not limited to alcoholic blended drinks, fruit beer drinks, added type grape wine, flavored grape wine drinks and the like. The hawthorn flavone-total tanshinone composition is found out to be able to prevent and treat non-alcoholic fatty liver, obesity and hyperlipidemia caused by long-term feeding with high-fat feeds. The oxidation resistance of hawthorn and the lipid-lowering effect of salvia miltiorrhiza are fully combined, all pathological indicators are improved comprehensively, and the non-alcoholic liver disease and obesity are alleviated. The composition is relatively simple, the dosage is relatively low, and the adverse reactions and the burden of liver and kidney are obviously reduced.

The invention discloses application of short-chain fatty acid in prevention or / and treatment of liver injury. The short-chain fatty acid is a product of intestinal flora glycolysis dietary fibers, belongs to an endogenous substance, is small in toxic and side effects, simple in structure, easy to metabolize, convenient to obtain and low in price, and can inhibit liver fatty degeneration and liver inflammation, improve liver functions and prevent or / and treat liver injury.

The invention relates to a medicine for treating hepatic adipose infiltration and hepatic fibrosis. The medicine for treating the hepatic adipose infiltration and the hepatic fibrosis is prepared from the following bulk drugs: cordyceps sinensis, typha angustifolia, pericarpium citri reticulatae and semen pruni. The medicine provided by the invention has the effects that the contents of total cholesterol and TG (Triglyceride) in a liver can be quite obviously decreased; the rise, which is caused by a composite factor, of the vitality of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) in a serum can be quite obviously decreased; further, the immunity can be improved; the hepatic fibroplasias can be obviously suppressed. The medicine for treating the hepatic adipose infiltration and the hepatic fibrosis is mainly used for invigorating spleen and kidney, eliminating blood stasis and removing dampness through diuresis; the effectiveness of treating the hepatic adipose infiltration is realized from the nature of a disease.

The invention relates to a composition with an effect of reducing the content of triglyceride of liver and a preparation method thereof and further relates to an application of the composition in foods, health foods or drugs. The composition with the effect of reducing the content of triglyceride of liver is prepared from the following components in parts by weight: 15-40 parts of lalang grass rhizome, 40-60 parts of roots of kudzu vines, 15-40 parts of mulberries, 5-15 parts of smoked plums, 1-8 parts of tea and 50-110 parts of corn oligopeptide. The technical point of the composition provided by the invention lies in that traditional medicinal varieties which has a long edible history and novel resource food raw materials are used together, the medicines are matched to be used according to the effect characteristics of the materials; the combination and proportion of the composition with a remarkable effect for reducing the weight of the liver and the content of triglyceride in the liver can be discovered by virtue of activity screening through zoological experiments.

The invention discloses a medicinal composition for preventing or treating nonalcoholic steatohepatitis. The composition consists of gynostemma pentaphylla, radix curcumae, rhizoma atractylodis macrocephalae, silybum marianum, rhizoma alismatis, poria cocos, semen cassiae, salvia miltiorrhiza, seman sinapis albae and hawthorn. The medicinal composition disclosed by the invention has the functions of invigorating the spleen, soothing the liver, activating blood and eliminating turbid, and has an obvious effect on preventing or treating nonalcoholic steatohepatitis.

The invention relates to the field of medicament preparation, and particularly relates to applications of a Periostin gene and a Periostin antibody in preparation of medicaments. The Periostin gene expression is closely relevant to the occurrence and development of NAFLD (Nonalcoholic Fatty Liver Disease) and hyperlipidemia through remarkable expression increase of the Periostin gene in the liver of a high-fat diet-induced obesity mouse, the significant expression rise of Periostin in a patient with fatty liver, and obvious positive correlation between the Periostin and liver TG (Triglyceride) content as well as serum TG content, and the Periostin gene and the Periostin antibody can be used for preparing and screening a NAFLD reagent and a hyperlipidemia reagent. The Periostin antibody can be used for neutralizing Periostin in the obese mouse body, obviously reducing the liver / weight ratio, and the TG content of the liver and serum, therefore, the Periostin antibody achieves the effects of obviously improving the development of the NAFLD and reducing the TG content in serum.

The invention discloses a drug composition composed of kaempferol, beta-sitosterol and / or tanshinone I and application thereof to preparing alcoholic liver disease treating and preventing drugs. The drug composition is composed of 3-55% of the kaempferol, 10-60% of the beta-sitosterol and 20-80% of the tanshinone I, and an independently applicable drug is composed of 0.5-70% of the kaempferol, 0.03-70% of the beta-sitosterol and 1.5-99% of the tanshinone I. implementing mice alcoholic liver injury models proves the therapeutic effects of the kaempferol, the beta-sitosterol, the tanshinone I and the drug composition on alcoholic liver diseases. Both the drug and the drug composition can effectively reduce liver lesions, particularly, significantly reduce hepatomegaly and weight increment, significantly decrease activity of serum transaminase and intrahepatic triglyceride content, and significantly improve tissue fat accumulation and inflammatory infiltration. The drugs can all prevent and treat alcoholic liver diseases, and also, can independently serve as drugs and be applied to developing corresponding drugs and healthcare products.

The invention provides the application of oligostilbene compounds in the preparation of drugs for the prevention and / or treatment of glucose and lipid metabolism disorders, and the activity research of 9 kinds of oligostilbene compounds extracted from the seeds of Sperus chinensis is carried out, and the compounds are verified It can inhibit the differentiation of fat cells, improve insulin resistance, and improve the sensitivity of fat cells to insulin, so as to prepare drugs for preventing or treating obesity, type II diabetes and other metabolic disorders.

The invention discloses a purpose of rhapontin in preparation of a medicine for treating insulin-resistant relevant diseases. Seven kinds of compounds are extracted from fenugreek; the several kinds of compounds are subjected to activity study; 3T3-L1 cells are used for building an insulin resistance (IR) module; the blood sugar lowering activity of the compound is further subjected to deep studyfrom the mitochondrion dysfunction level; the prevention and treatment mechanism of the seven compounds on diabetes mellitus is discussed. The result shows that the compound can inhibit the 3T3-L1 cell differentiation; the lipid droplet accumulation is inhibited; the TG content is reduced; the fat factor transcription level can be reduced through relevant signal paths; in addition, by lowering thelevel of ROS in the cells, the compound recovers the 3T3-L1 cell mitochondrion membrane potential; the generation of ATP in the cells is generated; the mitochondrion DNA injury is prevented; the mitochondrion generation is promoted.

The invention relates to application of MAGLII-11 in preparation of a medicine for preventing or treating alcoholic fatty liver, and belongs to the field of medicine. The invention aims to provide application of the compound in preparation of medicines for preventing or treating alcoholic fatty liver, and the compound is good in treatment effect and high in safety. The MAGLII-11 has a remarkable treatment effect on alcoholic fatty liver, can reduce ALT and AST, reduce TG content, TC content and LDL-C content and improve serum HDL-C content, has remarkable lipid-lowering and liver-protecting effects, and has a remarkable medical prospect.

The invention provides a compound liver-protecting traditional Chinese medicine for treating non-alcoholic fatty liver, which comprises the following components in parts by weight: 2-10 parts by weight of chitosan oligosaccharide, 3-20 parts by weight of salidroside, 5-10 parts by weight of resveratrol, 10-20 parts by weight of astaxanthin and 5-15 parts by weight of sea cucumber glycosaminoglycan. In the present invention, through in vivo and in vitro experiments on NAFLD mouse models, five bioactive components of salidroside, chitosan, resveratrol, chitosan and sea cucumber glycosaminoglycans have been determined by cell and molecular biology methods. After the scientific proportioning, it can regulate the genes related to lipid metabolism, significantly reduce the content of triglyceride in NAFLD liver cells, reduce the apoptosis induced by fatty acids, reduce the hepatic steatosis of high-fat diet mice, and reduce the intrahepatic TG content, and no obvious side effects, no cytotoxicity, will not destroy the body's own immune balance.